Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arterra Bioscience SpAMIL:ARBS -0.33%77 Gross Margin % is 98.04% as of Dec. 2025, which is 12% above its 10-year median of 87.16. GuruFocus rates MIL:ARBS with a GF Score™ of 77/100 and a GF Value™ of €2.91 (Fairly Valued). Among 732 Biotechnology companies, Arterra Bioscience SpA ranks better than 89.48% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Arterra Bioscience SpA had a gross margin of 98.04% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Arterra Bioscience SpA Gross Margin % Related Terms
Arterra Bioscience SpA Gross Margin % Historical Data
* Premium members only.
The historical data trend for Arterra Bioscience SpA's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:ARBS vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Arterra Bioscience SpA's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arterra Bioscience SpA Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arterra Bioscience SpA's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Arterra Bioscience SpA's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Arterra Bioscience SpA (MIL:ARBS) has a Gross Margin % of 98.04% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Arterra Bioscience SpA and its competitors. This is 12% above median its historical median of 87.16. Over the past decade, Arterra Bioscience SpA's Gross Margin % has ranged from 83.31 to 97.47. According to the industry distribution chart, Arterra Bioscience SpA ranks #77 out of 732 companies in the Biotechnology industry, placing it in the top 10.5%.
Is Arterra Bioscience SpA's Gross Margin % too high?
Arterra Bioscience SpA's current Gross Margin % of 98.04% is 12% above median its 10-year median of 87.16. Over the past 10 years, this metric has ranged from a low of 83.31 to a high of 97.47. The Biotechnology industry median Gross Margin % is 60.91. Arterra Bioscience SpA's value of 98.04% is 61% above this industry median. Based on the distribution chart, Arterra Bioscience SpA ranks #77 out of 732 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arterra Bioscience SpA has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arterra Bioscience SpA's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arterra Bioscience SpA ranks #77 out of 732 companies for Gross Margin %. This places Arterra Bioscience SpA in the top 11% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Arterra Bioscience SpA's value of 98.04% is 61% above this benchmark. Historically, Arterra Bioscience SpA's own Gross Margin % has ranged from 83.31 to 97.47 over the past decade. While the company's 10-year median is 87.16 vs. the industry median of 60.91, Arterra Bioscience SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arterra Bioscience SpA's current Gross Margin % of 98.04% is 61% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Arterra Bioscience SpA and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arterra Bioscience SpA's current Gross Margin % is 98.04%, which is 12% above median its own 10-year median of 87.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arterra Bioscience SpA stock overvalued right now?
Based on GuruFocus' analysis, Arterra Bioscience SpA (MIL:ARBS) is currently considered Fairly Valued. The stock's GF Value™ is €2.91, compared to a current price of €3.04 — trading 4.5% above its estimated fair value. The current Gross Margin % is 98.04%, which is 12% above median its 10-year median of 87.16 and 61% above the Biotechnology industry median of 60.91. Arterra Bioscience SpA's overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Arterra Bioscience SpA (MIL:ARBS), the current Gross Margin % is 98.04% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arterra Bioscience SpA (MIL:ARBS) Overvalued in 2026?
Based on GuruFocus' analysis, Arterra Bioscience SpA stock appears to be overvalued.
The current stock price of €3.04 is trading 4.5% above its estimated GF Value™ of €2.91.
GuruFocus considers Arterra Bioscience SpA to be Fairly Valued.
Key valuation signals for MIL:ARBS:
Gross Margin %: 98.04% (12% above median its 10-year median of 87.16)
GF Value™: €2.91 vs. price of €3.04 (4.5% above fair value)
Industry Position: 61% above the Biotechnology median (#77 of 732)
No single metric tells the full story. See the MIL:ARBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.
77GF Score
Get the complete analysis for MIL:ARBS
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:ARBS has been successfully added to your 
